Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 2/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 2/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18863746 | 0.83 | ACHE (0.45) | ACHESMN1; SMN2TMEM97SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL18334635 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2NPY1RCA2 | |
| SCHEMBL17039661 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL18863735 | 0.76 | FOLH1 (0.50) | CA2 | |
| SCHEMBL2582068 | 0.74 | ALDH1A1 (0.44) | SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL30337983 | 0.70 | SMN1; SMN2 (0.60) | SMN1; SMN2CA2MLYCD | |
| SCHEMBL17039700 | 0.69 | SMN1; SMN2 (0.55) | SMN1; SMN2 | |
| SCHEMBL10064731 | 0.68 | SMN1; SMN2 (0.84) | SMN1; SMN2CA2 | |
| SCHEMBL28984149 | 0.68 | SMN1; SMN2 (0.84) | SMN1; SMN2CA2 | |
| SCHEMBL28510822 | 0.68 | CHEK1 (0.37) | SMN1; SMN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286285-B2 | Modified biotin, streptavidin mutant, and usage of them | SAVID THERAPEUTICS INC. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-20170145063-A1 | MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM | SAVID THERAPEUTICS INC. (JP) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145063-A1 | MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM | BTD, HLCS, BROX | ACHE 4415/4885SMN1; SMN2 4476/4885NPY1R 3182/4885 |
| US-11286285-B2 | Modified biotin, streptavidin mutant, and usage of them | BTD, HLCS, BROX | ACHE 4415/4885SMN1; SMN2 4476/4885NPY1R 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.